Intensity therapeutics ipo
WebApr 20, 2024 · Intensity Therapeutics, a Phase 1/2 biotech developing intratumoral injection therapies for cancer, filed a new blank prospectus with the SEC on Wednesday, with plans to raise $17 million. The company had most recently planned to raise $15 million by offering 2.1 million shares at a price range of $6 to $8. WebRenaissance Capital — Solid tumor biotech Intensity Therapeutics sets proposed price at $4.50 ahead of $8 million IPO News • Jan 13, 2024 Renaissance Capital — Solid tumor biotech Intensity Therapeutics lowers share offering by 20% ahead of $8 million IPO Find More Contacts for Intensity Therapeutics Lew Bender CEO, Founder, President
Intensity therapeutics ipo
Did you know?
WebIn 2024, the Company executed a clinical collaboration agreement with Bristol Myers Squibb (BMS) to evaluate the combination of the Company’s lead product, INT230-6, with BMS’s anti-CTLA-4 antibody, Yervoy® (ipilimumab), in patients with advanced sarcoma, breast, and liver cancers. The cohorts are open to enrollment. WebInvestors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
WebNov 11, 2024 · Intensity Therapeutics, Inc (NASDAQ:INTS) IPO will take place October, 19 on the NASDAQ exchange under the ticker INTS. The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on April 17, 2024. WebIntensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and …
WebMar 13, 2024 · A far more modest IPO is also in the works courtesy of Intensity Therapeutics, which is offering over 1.7 million shares of common stock at an estimated price of $4.50 apiece. If all goes to plan, the cancer-focused company expects total proceeds of $6.1 million, rising to $7.2 million if underwriters take advantage of the option … WebIntensity Therapeutics is registered under the ticker NASDAQ:INTS . Their stock opened with $4.50 in its Feb 2, 2024 IPO. Stock Symbol NASDAQ:INTS Money Raised at IPO $8.1M IPO Share Price $4.50 IPO Date Feb 2, 2024 Stock chart by Investors Number of Lead Investors 1 Number of Investors 5 Intensity Therapeutics is funded by 5 investors.
WebSep 22, 2024 · Intensity Therapeutics has filed to raise $10 million in an IPO. The firm is developing intratumoral injection treatment approaches for various cancer conditions. Intensity Therapeutics...
WebStructure finalizes $111M IPO; Intensity plots offering Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Research Biotech Medtech CRO Special Reports Trending Topics... child development stranger anxietyWebOct 18, 2024 · Intensity Therapeutics, Inc (NASDAQ: INTS) IPO will take place October, 19 on the NASDAQ exchange under the ticker INTS. The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on April 17, 2024. Intensity Therapeutics, Inc is a clinical-stage biotechnology company ... child development support corp brooklyn nyWebOur Story Intensity Therapeutics is a clinical-stage biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing first-in-class cancer drugs that attenuate tumors with minimal side effects, while training the patient’s own immune system to fight the cancer. Our lead product … go-to-market strategy 策略